Page 373 - Traité de chimie thérapeutique 6 Médicaments antitumoraux

14. CAMPTOTHECINE ETDÉRIVES 329

DUNTON C., New options for the treatment of advanced ovarian cancer, Seminars in
Oncology, 1997, 24, S-2, 2-11.
JAILLON-ABRAHAM C., Topotécan : un nouveau mécanisme d'action pour le traitement
du cancer de l'ovaire, Cancérol. Auj., 1997, 6, 75-79.
COMPOSÉS EN DÉVELOPPEMENT
WANI M. et al., Resolution of a key tricyclic synthon for total synthesis and antitumor
activity of camptothecin, J. Med. Chem., 1987, 30, 2313-2319.
LUZZIO M. et al., Synthesis and antitumor activity of nove! water soluble derivatives of
camptothecin as specific inhibitors of topoisomerase l, J. Med. Chem., 1995, 38, 395-
401.
HENEGAR K., Practical asymmetric synthesis of (S)-4-ethyl-7,8-dihydro-4-hydroxy-1H-
pyrano[3,4-f]indolizine-3,6, 10(4/)-trione, a key intermediate for the synthesis of irino-
tecan and other camptothecin analogs, J. Org. Chem., 1997, 94, 6588-6597.
LAVERGNE O. etal., BN 80245 : an E-ring modified camptothecin with potent antiproli-
ferative and topoisomerase I inhibitory activities, Bioorg. Med. Chem. Letters, 1997,
7, 2235-2238.
FAN Y., Molecular modeling studies of the DNA-topoisomerase I ternary cleavable com-
plex with camptothecin, J. Med. Chem., 1998, 41, 2216-2226.
LAVERGNE O. et al., Synthesis and antitumor activity of novel E-ring-modified campto-
thecin analogues, J. Med. Chem., 1998, 41, 5410-5419.
SUGIMORI M. et al., Synthesis and antitumor actlvity of ring A and F modified hexacyclic
camptothecin analogues, J. Mead. Chem., 1998, 41, 2308-2318.
BOM D., BURKE K. et al., The novai silatecan 7-tert-butyldimethylsilyl-10-hydroxycamp-
tothecin displays high lipophllicity, improved human blood stability and potent anti-
cancer activity, J. Med. Chem., 2000, 43, 3970-3980.